Benzinga | Jan 15, 2021 10:31AM EST

B. Riley FBR Downgrades Arcturus Therapeutics to Neutral, Lowers Price Target to $77

B. Riley FBR analyst Mayank Mamtani downgrades Arcturus Therapeutics (NASDAQ:ARCT) from Buy to Neutral and lowers the price target from $138 to $77.